CC Chemokine Receptor Type 5 Market Report 2026

CC Chemokine Receptor Type 5 Market Overview

• CC Chemokine Receptor Type 5 market size has reached to $1.54 billion in 2025 • Expected to grow to $2.48 billion in 2030 at a compound annual growth rate (CAGR) of 9.9% • Growth Driver: Increasing Prevalence Of Chronic Diseases On The CC Chemokine Receptor Type 5 Market • Market Trend: Development Of CCR5 Antagonists For Chronic Disease Treatment • North America was the largest region in 2025.

What Is Covered Under CC Chemokine Receptor Type 5 Market?

CC chemokine receptor type 5 (CCR5) refers to a protein located on the surface of white blood cells that plays a key role in the immune system by acting as a receptor for certain chemokines, which are signaling molecules that direct the movement of immune cells towards sites of inflammation or infection. It is involved in the pathogenesis of diseases such as HIV, where it serves as a co-receptor, allowing the virus to enter and infect host cells, making it a target for therapeutic interventions. The main types of CC chemokine receptor type 5 are BMS-813160, AG-1105, CCL-14, DS-001, and others. BMS-813160 refers to a small-molecule inhibitor a compound developed by Bristol-Myers Squibb that targets specific receptors or pathways and is often studied for its potential therapeutic effects in various diseases, including cancer. The various distribution channels include hospitals, clinics, online pharmacies, and retail pharmacies. The various applications involve infectious disease, gastrointestinal, immunology, oncology, and others and are used by different end-users such as research institutes, pharmaceutical companies, and healthcare facilities.

What Is The CC Chemokine Receptor Type 5 Market Growth Forecast?

The cc chemokine receptor type 5 market size is expected to see strong growth in the next few years. It will grow to $2.48 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to expansion of personalized immunotherapies, increasing hiv treatment innovation, rising oncology drug development pipelines, growing investment in immune modulation research, advancements in targeted receptor drug design. Major trends in the forecast period include increasing development of ccr5 antagonist therapies, rising focus on hiv and immunology research, expansion of ccr5 applications in oncology, growing adoption of targeted immune modulation, enhanced emphasis on precision drug development.

Global CC Chemokine Receptor Type 5 Market Segmentation

1) By Type: BMS-813160, AG-1105, DS-001, Other Types 2) By Distribution Channel: Hospitals, Clinics 3) By Application: Infectious Disease, Immunology, Oncology, Other Applications 4) By End User: Research Institutes, Pharmaceutical Companies, Healthcare Facilities Subsegments: 1) By BMS-813160: CCR5 Antagonist For HIV Treatment, CCR5 Antagonist For Inflammatory Diseases 2) By AG-1105: CCR5 Antagonist For Autoimmune Disorders, CCR5 Antagonist For Cancer Therapy 3) By DS-001: CCR5 Inhibitor For Cancer Treatment, DS-001 For Inflammatory Disease Management 4) By Other Types: Novel CCR5 Antagonists, Dual-Target CCR5 Antagonists

What Are The Drivers Of The CC Chemokine Receptor Type 5 Market?

The increasing prevalence of chronic diseases is expected to propel the growth of the CC chemokine receptor type 5 market going forward. Chronic diseases refers to long-term medical conditions, such as heart disease, diabetes, and arthritis, that progress slowly and often require ongoing management. The prevalence of chronic diseases is growing due to aging populations and increasing rates of lifestyle-related risk factors such as poor diet, physical inactivity, and obesity. CC Chemokine Receptor Type 5 (CCR5) is crucial in chronic diseases such as human immunodeficiency virus (HIV), as it acts as a coreceptor that allows the virus to enter and infect immune cells, playing a key role in the progression of the disease. For instance, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency. in 2023, approximately 194 million U.S. adults, or 76.4%, reported having at least one chronic condition. The prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the increasing prevalence of chronic diseases is driving the growth of the CC chemokine receptor type 5 industry. The rising HIV prevalence is expected to propel the growth of the CC chemokine receptor type 5 market going forward. HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, weakening the body’s ability to fight infections and diseases. Increasing HIV is driven by unsafe sexual practices, which allow the virus to spread more easily between individuals. CC Chemokine Receptor Type 5 (CCR5) helps HIV by acting as a co-receptor that the virus uses, along with CD4, to enter and infect immune cells, enabling viral replication. For instance, in October 2025, according to the Minority HIV/AIDS Fund (MHAF), a US-based government agency, an estimated 39.9 million individuals worldwide were living with HIV in 2023, consisting of 38.6 million adults and 1.4 million children, compared to previous years. Therefore, the rising HIV prevalence is driving the growth of the CC chemokine receptor type 5 industry.

Key Players In The Global CC Chemokine Receptor Type 5 Market

Major companies operating in the cc chemokine receptor type 5 market are Cytodyn Inc., Gilead Sciences Inc., ViiV Healthcare Limited, Pfizer Inc., Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, AbbVie Inc., AstraZeneca plc, Novartis AG, Sanofi SA, Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Ono Pharmaceutical Co Ltd, Avexa Limited, Incyte Corporation, Humanigen Inc., Biogen Inc.

Global CC Chemokine Receptor Type 5 Market Trends and Insights

Major companies operating in the CC chemokine receptor type 5 market are focused on developing new drugs, such as a CCR5 antagonist, to gain a competitive advantage. A CC chemokine receptor type 5 (CCR5) antagonist is a type of drug that blocks the CC chemokine receptor type 5 (CCR5) receptor on immune cells, preventing certain pathogens such as HIV from binding and entering these cells, thereby inhibiting infection and modulating immune responses. For instance, in February 2024, CytoDyn Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on leronlimab. The company is now authorized to continue with its planned HIV clinical trial to investigate leronlimab's impact on chronic inflammation. Leronlimab, a CCR5 antagonist (also known as PRO 140), shows promise for various therapeutic applications due to its potential to target multiple health conditions and is being investigated for various indications, including HIV and cancer.

Regional Outlook

North America was the largest region in the CC chemokine receptor type 5 market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the CC Chemokine Receptor Type 5 Market?

The CC chemokine receptor type 5 market consists of sales of receptor antagonists, monoclonal antibodies, small molecule inhibitors, and gene editing therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the CC Chemokine Receptor Type 5 Market Report 2026?

The cc chemokine receptor type 5 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cc chemokine receptor type 5 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.